Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project
Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project
复制标题
DOI：
10.1017/s1041610208008132
复制
发表时间：
2009-02-01
影响因子：
7
通讯作者：
Yamaguchi, Satoshi
中科院分区：
文献类型：
--
作者：
Ishii, Hiroshi;Ishikawa, Hiroyasu;Yamaguchi, Satoshi
背景：一些随访[F-18]氟脱氧葡萄糖(FDG)-正电子发射断层扫描（PET）研究已经在轻度认知障碍患者中进行，但没有一个研究对象的临床痴呆评分（CDR）为0.5。因此，我们使用FDG-PET来研究CDR 0.5转化为痴呆的患者的基线葡萄糖代谢（CMRglc）是否显示出与早期阿尔茨海默病（AD）一致的变化。方法：基于我们早期的研究，我们称之为1998年的患病率研究，我们能够用PET检查14例CDR 0, 42例CDR 0.5和12例AD受试者，并对这些受试者进行了5年的随访。比较CDR 0、CDR 0.5/转换者、CDR 0.5/非转换者和AD受试者的基线神经心理学和CMRglc值。结果：所有CDR 0的受试者在5年后被重新评估为CDR 0。在CDR为0.5的受试者中，20人转化为AD， 22人仍为CDR为0.5。在认知测试中，在基线评估中，与CDR 0.5/非转换者相比，CDR 0.5/转换者的近期记忆功能明显恶化。AD患者大部分脑区CMRglc下降。与CDR 0.5/非转换组相比，CDR 0.5/转换组在右侧扣带、左侧顶叶下回和左侧颞回的基线CMRglc显著降低。结论：我们的研究结果表明，CDR 0.5/转换者在AD特异性区域有基线代谢下降。
Background: Several follow-up [F-18]fluorodeoxy glucose (FDG)-positron emission tomography (PET) studies have been performed in patients with mild cognitive impairment, but none have examined subjects with a Clinical Dementia Rating (CDR) of 0.5. Therefore, we used FDG-PET to investigate whether baseline glucose metabolism (CMRglc) in CDR 0.5 converters to dementia showed changes consistent with early Alzheimer's disease (AD).Methods: Based on our earlier study, which we refer to as Prevalence Study 1998, we were able to examine 14 CDR 0, 42 CDR 0.5, and 12 AD subjects with PET and follow these subjects for five years. Baseline neuropsychological and CMRglc values were compared among groups of CDR 0, CDR 0.5/converters, CDR 0.5/non-converters, and AD subjects.Results: All CDR 0 subjects were reassessed as CDR 0 after the five-year period. For CDR 0.5 subjects, 20 had converted to AD and 22 remained as CDR 0.5. In cognitive tests, CDR 0.5/converters showed significantly deteriorated recent memory function compared with CDR 0.5/non-converters at the baseline evaluation. Most brain areas showed decreased CMRglc in AD patients. CDR 0.5/converters had a significantly lower baseline CMRglc in the right cingulate, left inferior parietal and left temporal gyrus compared with CDR 0.5/non-converters.Conclusions: Our findings suggest that CDR 0.5/converters have a baseline metabolic decline in areas that might be specific to AD.